Updates in HER2+ mBC

University of Colorado Cancer Center
E

Triplet Targeting Combination in HR+/HER2+ BC: Understanding Signaling Converge at Cell Cycle Checkpoints

By University of Colorado Cancer Center FEATURING Elena Shagisultanova
By University of Colorado Cancer Center FEATURING Elena Shagisultanova
303 views
June 23, 2021
Comments 0
Login to view comments. Click here to Login
15:07

2021 ASCO Review on AntiHER2 Antibody-Drug Conjugates in BC: DESTINY…

Guy Jerusalem

169 views
09:37

Trastuzumab Deruxtecan for HER2+ MBC With Brain Mets: DESTINY-Breast…

Nicole Williams

661 views
06:25

ASCO 2021 Comparison of Standard Anti-HER2 Directed Approaches in MB…

Hans-Christian Kolberg

460 views
16:11

2021 ASCO Updates: Hunting for HER2 in Solid Tumors

Erika Hamilton

132 views
22:37

Case Study Discussion on HER2+ MBC: Trastuzumab Deruxtecan in Heavil…

2021 Virtual Best of Breast

P. Anderson, S. Badve, E. Hamilton, R. L. Mahtani

254 views
15:12

Advances in HER2+ BC: Overview of Current Data

2021 Community Oncology Conference

J. O'Shaughnessy

695 views
13:51

Management of HER2+ MBC: Surveying the Data for ADC, TKI, and Novel …

Total Health

T. Traina, L. Carey

506 views
14:57

Colorado University Highlights on BC Research: Inhibiting Tumor Cell…

University of Colorado Cancer Center

H. Ford, J. Richer, T. Lyons

132 views
06:29

Ongoing Therapy Escalation Trials in HER2+ BC: COMPASSHER2 Data, Tre…

Total Health

J. Meisel, H. Soliman

681 views
04:35

HER2+ Breast Cancer: Optimizing Quality of Life

Virginia Kaklamani

456 views